American Association for Cancer Research (AACR)
April 17, 2023
Preclinical testing of therapeutic biologics using patient-derived 3D spheroids.
April 16, 2023Perfused patient-derived tumor organoid models with autologous immune cells for preclinical drug development.
June 5, 2022
Abstract ID 2031: Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis.
April 13, 2022
Dissecting personalized PD-1 inhibitor efficacy using patient-derived 3D spheroids.
April 12, 2022
3D Predict™, an analytically and clinically validated platform for evidence-based functional precision medicine.
Organoids standardized to a clinically validated drugs response assay for truly predictive in vitro drug response profiling.
April 10, 2022
Ex vivo 3D drug response profiling of XPDX-derived tumor cells for acceleration of preclinical drug development.
Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response.
Engineered 3D tissues facilitate preclinical immunotherapy studies in fully human platforms.
Society for Neuro-Oncology (SNO)
November 18, 2022
Functional ex vivo testing prospectively identifies newly diagnosed glioblastoma patients sensitive to temozolomide treatment irrespective of MGMT methylation status.
Society for Immunotherapy of Cancer (SITC)
November 11, 2022
Abstract #162: Detecting T-cell reinvigoration and persistence using patient-derived ex vivo three-dimensional spheroid models.
Analyzing the modeling of T-cell specific immunotherapies
Kiyatec’s innovative ex vivo human tumor models, featuring a combination of tumor cells, stromal cells, and autologous immune cells, serve as a crucial tool in mitigating risks in preclinical immunotherapy development. These models enable the study of T-cell persistence and activity within ex vivo cultures, showcasing their potential utility in assessing T-cell specific therapies, including checkpoint inhibitors, bispecifics, and cellular therapies.
Presented by Tessa DesRochers, PhD
7th Tumor Models for Immuno-Oncology Summit
January 25, 2023
Ex vivo 3D cell culture technology for predicting individualized therapeutic response.
Microtumor technology for investigating long-term drug response.